Results 261 to 270 of about 92,209 (296)
Some of the next articles are maybe not open access.
Pediatrics In Review, 2016
1. Lynn Smitherman, MD* 1. *Wayne State University School of Medicine, Detroit, MI. 1. 1. Tay E. Azole Antifungal Agents. Tay E. Pediatr Rev. 2005;26(1):20–21 [OpenUrl][1][FREE Full Text][2] 2. 1. Jura S, 2. Hillenbrand K. Fluconazole. Jura S, Hillenbrand K. Pediatr Rev. 2006;27(4):158–159 [OpenUrl][3]
openaire +2 more sources
1. Lynn Smitherman, MD* 1. *Wayne State University School of Medicine, Detroit, MI. 1. 1. Tay E. Azole Antifungal Agents. Tay E. Pediatr Rev. 2005;26(1):20–21 [OpenUrl][1][FREE Full Text][2] 2. 1. Jura S, 2. Hillenbrand K. Fluconazole. Jura S, Hillenbrand K. Pediatr Rev. 2006;27(4):158–159 [OpenUrl][3]
openaire +2 more sources
1992
The allylammes constitute a recently developed class of synthetic antimycotics characterized functionally by their action as squalene epoxidase inhibitors.1 Figure 6–1 shows the structures of three representative allylamines. Naftifine, the first of these compounds to be discovered, was first synthesized in 1974,2 and its antifungal properties were ...
N S, Ryder, H, Mieth
openaire +2 more sources
The allylammes constitute a recently developed class of synthetic antimycotics characterized functionally by their action as squalene epoxidase inhibitors.1 Figure 6–1 shows the structures of three representative allylamines. Naftifine, the first of these compounds to be discovered, was first synthesized in 1974,2 and its antifungal properties were ...
N S, Ryder, H, Mieth
openaire +2 more sources
ORAL ANTIFUNGAL DRUG INTERACTIONS
Dermatologic Clinics, 1997The recent approval of itraconazole and terbafine for the treatment of onychomycosis has launched a new era in the therapeutic management of this previously resistant form of dermatomycoses. These agents represent safe and effective treatments. The clinician should, however, become knowledgeable with the potential drug interactions that are discussed ...
H I, Katz, A K, Gupta
openaire +2 more sources
Journal of Current Hematology & Oncology Research, 2023
Fungal infections continue to emerge as an important cause of infectious disease and mortality in humans. Amphotericin B deoxycholate (ABD), was the first antifungal that was discovered, and it was released in 1958, and flucytosine, which was developed later and is effective against Candida and Cryptococcus, was introduced in 1978.
İlknur Akkuş, Birgül Kaçmaz
openaire +1 more source
Fungal infections continue to emerge as an important cause of infectious disease and mortality in humans. Amphotericin B deoxycholate (ABD), was the first antifungal that was discovered, and it was released in 1958, and flucytosine, which was developed later and is effective against Candida and Cryptococcus, was introduced in 1978.
İlknur Akkuş, Birgül Kaçmaz
openaire +1 more source
Antifungal Drugs and Resistance
1995From the late 1950’s, extending for two decades thereafter, amphotericin B was the only broad spectrum antifungal drug which could be systemically administered. Because it was the only option, and because systemic mycoses were relatively infrequent, there was little interest in understanding the mechanism of action of amphotericin B, or expanding ...
openaire +2 more sources
Antifungal drugs on the horizon
Journal of the American Academy of Dermatology, 1994In the past 10 years there has been a major expansion in the development of antifungal drugs, but there are still weaknesses in the range and scope of current antifungal chemotherapy. New developments have included the modification of existing drug molecules to eliminate toxicity and improve activity, for instance, the development of the lipid ...
openaire +2 more sources
Current Opinion in Microbiology, 1999
There have been many new developments in antifungal therapy in the past few years. Some antifungal drugs have been reformulated to reduce toxicity (e.g. new lipid formulations of polyenes), and new derivatives of drugs have been developed to enhance potencies.
openaire +2 more sources
There have been many new developments in antifungal therapy in the past few years. Some antifungal drugs have been reformulated to reduce toxicity (e.g. new lipid formulations of polyenes), and new derivatives of drugs have been developed to enhance potencies.
openaire +2 more sources
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
Antifungals and antifungal drug discovery.
2012Abstract This chapter discusses: (1) important clinical aspects of invasive clinical mycoses, i.e., candidosis and aspergillosis; (2) current antifungal therapeutic options for invasive mycoses; (3) antifungal drug resistance; and (4) approaches to antifungal drug discovery, including identification of drug targets.
R. Calderone +6 more
openaire +1 more source
1998
Abstract Amphotericin B has been the mainstay of systemic antifungal therapy for decades, but the toxicity associated with parenteral administration of the drug has led to a search for effective, less toxic, and more easily administered alternative drugs.
Peter G Pappas, John E Edwards
openaire +1 more source
Abstract Amphotericin B has been the mainstay of systemic antifungal therapy for decades, but the toxicity associated with parenteral administration of the drug has led to a search for effective, less toxic, and more easily administered alternative drugs.
Peter G Pappas, John E Edwards
openaire +1 more source